975 related articles for article (PubMed ID: 17289836)
1. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
[TBL] [Abstract][Full Text] [Related]
2. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
Deeb D; Jiang H; Gao X; Hafner MS; Wong H; Divine G; Chapman RA; Dulchavsky SA; Gautam SC
Mol Cancer Ther; 2004 Jul; 3(7):803-12. PubMed ID: 15252141
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-κB signalling inhibitor.
Omar HA; Arafa el-SA; Maghrabi IA; Weng JR
Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):464-71. PubMed ID: 24401154
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.
Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B
Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072
[TBL] [Abstract][Full Text] [Related]
5. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.
Aggarwal S; Ichikawa H; Takada Y; Sandur SK; Shishodia S; Aggarwal BB
Mol Pharmacol; 2006 Jan; 69(1):195-206. PubMed ID: 16219905
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis.
Deeb DD; Jiang H; Gao X; Divine G; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2005; 5(2):81-91. PubMed ID: 16471035
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells.
Lee TJ; Jang JH; Noh HJ; Park EJ; Choi KS; Kwon TK
J Cell Biochem; 2010 Apr; 109(5):885-95. PubMed ID: 20127709
[TBL] [Abstract][Full Text] [Related]
8. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
9. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
10. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways.
Thanaketpaisarn O; Waiwut P; Sakurai H; Saiki I
Int J Oncol; 2011 Jul; 39(1):279-85. PubMed ID: 21537836
[TBL] [Abstract][Full Text] [Related]
11. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
12. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
13. The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells.
Shimada K; Nakamura M; Ishida E; Kishi M; Matsuyoshi S; Konishi N
Mol Carcinog; 2004 Jan; 39(1):1-9. PubMed ID: 14694442
[TBL] [Abstract][Full Text] [Related]
14. Acacetin (5,7-dihydroxy-4'-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-κB/Akt signaling in prostate cancer cells.
Kim HR; Park CG; Jung JY
Int J Mol Med; 2014 Feb; 33(2):317-24. PubMed ID: 24285354
[TBL] [Abstract][Full Text] [Related]
15. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
Szliszka E; Helewski KJ; Mizgala E; Krol W
Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway.
Li Y; Sarkar FH
Clin Cancer Res; 2002 Jul; 8(7):2369-77. PubMed ID: 12114442
[TBL] [Abstract][Full Text] [Related]
18. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.
Festa M; Petrella A; Alfano S; Parente L
Int J Cancer; 2009 Jun; 124(11):2728-36. PubMed ID: 19230027
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer.
Andrzejewski T; Deeb D; Gao X; Danyluk A; Arbab AS; Dulchavsky SA; Gautam SC
Oncol Res; 2008; 17(6):257-67. PubMed ID: 19192720
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
